Cargando…

Increased Frequency of Myeloid-Derived Suppressor Cells in Myasthenia Gravis After Immunotherapy

Myeloid-derived suppressor cells (MDSCs) are a population of myeloid progenitor cells with immunoregulatory functions and their role in myasthenia gravis (MG) was unknown. In this study, we investigated the phenotypic and functional alterations of MDSCs in MG before and after immunotherapy. The freq...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Yan, Yan, Chong, Su, Caixia, Wang, Ying, Luo, Sushan, Lu, Jun, Zhao, Chongbo, Zhao, Gan, Xi, Jianying
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Neurology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9278661/ https://www.ncbi.nlm.nih.gov/pubmed/35847216 http://dx.doi.org/10.3389/fneur.2022.902384

Ejemplares similares

Efficacy and Safety of Immunotherapies in Refractory Myasthenia Gravis: A Systematic Review and Meta-Analysis
por: Feng, Xuelin, et al.
Publicado: (2021)

Comorbid Autoimmune Diseases in Patients With Myasthenia Gravis: A Retrospective Cross-Sectional Study of a Chinese Cohort
por: Shi, Jianquan, et al.
Publicado: (2021)

Clinical Features of Myasthenia Gravis With Antibodies to MuSK Based on Age at Onset: A Multicenter Retrospective Study in China
por: Zhou, Yufan, et al.
Publicado: (2022)

Pneumonia in myasthenia gravis: Microbial etiology and clinical management
por: Su, Manqiqige, et al.
Publicado: (2022)

A Targeted Complement Inhibitor CRIg/FH Protects Against Experimental Autoimmune Myasthenia Gravis in Rats via Immune Modulation
por: Song, Jie, et al.
Publicado: (2022)

Increased serum IL-2, IL-4, IL-5 and IL-12p70 levels in AChR subtype generalized myasthenia gravis
por: Huan, Xiao, et al.
Publicado: (2022)

From Traditional to Targeted Immunotherapy in Myasthenia Gravis: Prospects for Research
por: Mantegazza, Renato, et al.
Publicado: (2020)

Afterdischarges in Myasthenia Gravis
por: Yang, Li, et al.
Publicado: (2021)

Short-term outcome prediction for myasthenia gravis: an explainable machine learning model
por: Zhong, Huahua, et al.
Publicado: (2023)

Nomogram for short-term outcome assessment in AChR subtype generalized myasthenia gravis
por: Zhao, Rui, et al.
Publicado: (2021)

Lack of Immunotherapy as the Only Predictor of Secondary Generalization in Very-Late-Onset Myasthenia Gravis With Pure Ocular Onset
por: Zhao, Sijia, et al.
Publicado: (2022)

Novel Treatments in Myasthenia Gravis
por: Menon, Deepak, et al.
Publicado: (2020)

Management of Juvenile Myasthenia Gravis
por: O'Connell, Karen, et al.
Publicado: (2020)

Controversies in Ocular Myasthenia Gravis
por: Evoli, Amelia, et al.
Publicado: (2020)

Immunoregulatory Cells in Myasthenia Gravis
por: Wu, Ying, et al.
Publicado: (2020)

Editorial: Phenotypes of myasthenia gravis
por: Li, Hai-Feng, et al.
Publicado: (2022)

Rituximab treatment in myasthenia gravis
por: Vesperinas-Castro, Ana, et al.
Publicado: (2023)

Role of complement in myasthenia gravis
por: San, Pyae Phyo, et al.
Publicado: (2023)

Treatment of insomnia in myasthenia gravis—A prospective study on non-benzodiazepine hypnotics in the treatment of myasthenia gravis patients with insomnia
por: Yan, Jingwen, et al.
Publicado: (2023)

Risk factors for pregnancy-related clinical outcome in myasthenia gravis: a systemic review and meta-analysis
por: Su, Manqiqige, et al.
Publicado: (2022)

Effects of Mitophagy on Regulatory T Cell Function in Patients With Myasthenia Gravis
por: Wang, Na, et al.
Publicado: (2020)

Favorable Effects of Tacrolimus Monotherapy on Myasthenia Gravis Patients
por: Fan, Zhirong, et al.
Publicado: (2020)

Evaluation of the Quantitative Myasthenia Gravis Score and Grip Strength in Chinese Patients With Myasthenia Gravis: An Observational Study
por: Li, Jinghao, et al.
Publicado: (2021)

Corticosteroid Treatment-Resistance in Myasthenia Gravis
por: Kaminski, Henry J., et al.
Publicado: (2022)

User Involvement in Myasthenia Gravis Research
por: Gilhus, Nils Erik, et al.
Publicado: (2022)

Myasthenia Gravis Presenting as Bulbar Palsy
por: Gosain, Dhruv, et al.
Publicado: (2023)

Altered gut microbiota and metabolites in untreated myasthenia gravis patients
por: Ding, Xiao-Jun, et al.
Publicado: (2023)

Determinants of Quality of Life in Myasthenia Gravis Patients
por: Szczudlik, Piotr, et al.
Publicado: (2020)

A Review of Psychiatric Comorbidity in Myasthenia Gravis
por: Law, Christina, et al.
Publicado: (2020)

Immune Checkpoint Inhibitor-Induced Myasthenia Gravis
por: Huang, Yi-Te, et al.
Publicado: (2020)

Reappraisal of Oral Steroid Therapy for Myasthenia Gravis
por: Imai, Tomihiro, et al.
Publicado: (2020)

Myasthenia Gravis with Elderly Onset at Advanced Age
por: Hernandez Fustes, Otto Jesus, et al.
Publicado: (2020)

The Muscle Is Not a Passive Target in Myasthenia Gravis
por: Vilquin, Jean-Thomas, et al.
Publicado: (2019)

Editorial: News and Views in the Management of Myasthenia Gravis
por: Evoli, Amelia, et al.
Publicado: (2021)

Application of lymphoplasmapheresis in the treatment of severe myasthenia gravis
por: Duan, Weiwei, et al.
Publicado: (2022)

Galcanezumab-Induced Myasthenia Gravis-Like Symptoms
por: Mubaraki, Adnan A
Publicado: (2023)

A Case of Pembrolizumab-Induced Myasthenia Gravis
por: Kosick, Thomas I, et al.
Publicado: (2023)

Vitamin D Receptor Polymorphism and Myasthenia Gravis in Chinese Han Population
por: Han, Ji-Lan, et al.
Publicado: (2021)

Herpesvirus entry mediator on T cells as a protective factor for myasthenia gravis: A Mendelian randomization study
por: Zhong, Huahua, et al.
Publicado: (2022)

Regulatory B Cells Are Decreased and Functionally Impaired in Myasthenia Gravis Patients
por: Lin, Ye, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_htudn6tq1cih149qqbvg6goesh